期刊文献+

胃癌患者术前血清胸苷激酶-1水平与TNM分期、复发以及生存期的关系

Relationship between preoperative serum thymidine kinase-1 in the patients with gastric cancer and TNM staging,recurrence and lifetime
下载PDF
导出
摘要 目的探讨胃癌患者术前血清胸苷激酶1(STK1)水平与胃癌分期、复发以及患者生存期的关系。方法选择171例胃癌患者(其中Ⅰ期36例、Ⅱ期32例、Ⅲ期47例、Ⅳ期56例),采用化学发光免疫分析技术测定其STK1的含量,分析STK1水平与胃癌分期、复发及生存期的关系。结果不同TNM分期胃癌患者的STK1表达水平差异有统计学意义,TNM分期越高的患者其STK1水平越高(P<0.01)。STK1表达量高的患者易复发(P<0.05),生存期随STK1水平的升高而缩短(P<0.01)。结论胃癌患者术前STK1水平对肿瘤的病情判断和预后评估有一定的参考价值。 objective To investigate the relationship between preoperative serum thymidine kinase -1 (STK1) in the patients with gastric cancer and TNM staging, recurrence and lifetime. Methods The serum samples of 171 cases of gastric cancer patients (of which there were 36 cases in Stage I, 32 cases in Stage II, 47 cases in Stage III and 56 cases in Stage IV) were collected. Chemiluminescence immunoassay was used to detect the content of STK1, and the relationship between STK1 level and TNM staging, recurrence and lifetime. Results The patients of different TNM staging showed statistical difference in the STK1 level, the higher stage the patients, the higher level the STK1 level (P〈0.01). The patients with a higher STK1 level were prone to have recurrence (P〈0.05); their lifetime was shortened with the increase of STK1 level (P〈0.0I). Conclusion The preoperative serum STK1 level of gastric cancer patients has certain clinical value for the diagnosis and prognosis evaluation of tumors.
出处 《广东医科大学学报》 2017年第1期18-20,共3页 Journal of Guangdong Medical University
关键词 胸苷激酶1 胃癌 分期 复发 serum thumidine kinase l gastric cancer rumor staging recurrence
  • 相关文献

参考文献7

二级参考文献92

  • 1丛玉隆.临床实验室分析前质量管理及对策[J].中华检验医学杂志,2004,27(8):483-487. 被引量:425
  • 2温怀凯,刘素霞.胃癌患者血清Gastrin含量分析及临床意义[J].放射免疫学杂志,2006,19(1):9-11. 被引量:4
  • 3曹勤,冉志华,萧树东.血清胃蛋白酶原、胃泌素-17和幽门螺杆菌IgG抗体筛查萎缩性胃炎和胃癌[J].胃肠病学,2006,11(7):388-394. 被引量:113
  • 4AA Guskova, AV Zagurny, Myu Skoblov, et al. Skoblov Molecular Genetic Analysis of Thymidine Kinase of the Herpes Simplex Virus Type l[J].Molecular Biology, 2005,39(1): 137-140.
  • 5He E, Xu XH, Guan H, et al. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast,lung, and esophageal cancer and non-Hodgkin's lymphoma[J]. Nucleosides Nucleotides Nucleic Acids, 2010,29(4-6) : 352- 358.
  • 6Nisman B, Allweis T, Kaduri L, et al. Serum thymidine kinase 1 activity in breast cancer[J].Cancer Biomark,2010,7(2):65 -72.
  • 7He Q, Fornander T, Johansson H, et al. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer[J]. Anticancer Res, 2006,26(6C) :4753-4759.
  • 8He Q, Zhang P, Zou L, et al. Concentration of thymidine kinase 1 in serum(S-TK1) is a more sensitive proSferation marker in human solid tumors than its activity[J].Oncol Rep,2005,14(4):1 013-1019.
  • 9Kidd EA, Yu J, Li X, etal. Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer[J]. Clin Cancer Res, 2005 , 11 (7): 2612-2619.
  • 10L Zou, PG Zhang, S Zou, et al. The half-life of thymidine kinase 1 in serum measured by ECL dot blot: a potential marker for monitoring the response to surgery of patients with gastric cancer[J].The international Journal of biological Markers,2002, 17( 2): 135-140.

共引文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部